In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...